AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others

FluMist Home could be a test case for at-home vaccines against a backdrop of challenging regulatory shifts.

By Alexandra Pecci • Oct. 1, 2025

Top pharma industry conferences in 2026

Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.

By Meagan Parrish • Oct. 1, 2025

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?

The new treatment may only offer modest benefits, but could gain traction in a market with few other options.

By Kelly Bilodeau • Sept. 30, 2025

As obesity M&A heats up, pharmas could get ‘blinded by opportunity’

With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.

By Kelly Bilodeau • Sept. 29, 2025

Is pharma’s IRA pricing battle running out of steam?

Despite recent court losses, the legal tides could still turn in the industry’s favor.

By Meagan Parrish • Sept. 26, 2025

Can a multibillion-dollar deal put Pfizer in the obesity big leagues?

After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.

By Michael Gibney • Sept. 25, 2025

Why Xoma, a drug royalty firm, is hunting biotech ‘zombies’

The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do the right thing” for the ecosystem and liquidate them, its executives say.

By Gwendolyn Wu • Sept. 25, 2025

Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach

Why multi-specific antibodies are seeing a fresh surge of industry buzz.

By Kelly Bilodeau • Sept. 24, 2025

Lilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics

The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.

By Michael Gibney • Sept. 23, 2025

With DTC ads under fire, pharma companies need to pivot

An executive order from HHS doesn’t prohibit direct outreach to consumers, but drugmakers will need to rethink their outreach strategies.

By Kelly Bilodeau • Sept. 22, 2025

3 FDA approval firsts that could be around the corner

Several market-altering decisions are on the agency’s docket for the rest of 2025.

By Meagan Parrish • Sept. 19, 2025

How pharma can play a role in the $1 trillion healthcare reinvention

A report from PwC takes a long-term approach to the shifts in healthcare and finds that efficiency in R&D and adaptable business models will define the drugmaker of the future.

By Michael Gibney • Sept. 18, 2025

AI agents are coming to pharma. Here’s what it means for clinical trials.

The high-tech helpers could autonomously navigate tedious tasks — but have to be carefully implemented.

By Kelly Bilodeau • Sept. 17, 2025

From atop Mt. Fuji, a Takeda team heralds a need for human plasma

The climb aimed to raise money and awareness as Takeda ramps up its plasma-derived therapy presence in Japan.

By Alexandra Pecci • Sept. 16, 2025

Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?

While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

By Kelly Bilodeau • Sept. 15, 2025

4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next

The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.

By Meagan Parrish • Sept. 12, 2025

Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.

Growing research suggests various ways weight loss drugs could have an impact in cancer care.

By Michael Gibney • Sept. 11, 2025

A new class of sleep drugs draws Wall Street’s attention

Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.

By Jacob Bell • Sept. 10, 2025

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

While the EU and UK attempt to lure scientists with new financial incentives, Basel’s stable economy and emphasis on science remains a draw.

By Alexandra Pecci • Sept. 10, 2025

At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves

Robert F. Kennedy Jr. faced criticism Thursday even from Republican lawmakers over changes to federal vaccine policy as well as a leadership crisis at the CDC.

By Delilah Alvarado , Jonathan Gardner • Sept. 5, 2025

Why drugmakers may need to borrow from quantum theory to confront tariff and pricing threats

With so many unknowns surrounding regulatory and policy shifts, pharma companies might need to consider fundamental changes to how they operate, a Deloitte analyst said.

By Michael Gibney • Sept. 3, 2025

How AI advances will shape the drugmaker of the future

An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.

By Michael Gibney • Sept. 2, 2025

FDA approves updated COVID boosters, but narrows use

In a post on X, HHS Secretary Robert F. Kennedy said the FDA has cleared vaccines from Pfizer, Moderna and Novavax for use in "high risk" individuals.

By Delilah Alvarado • Updated Aug. 27, 2025

A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant

Newcomers looking for a way into the obesity space are developing unique methods to snag market share.

By Amy Baxter • Aug. 27, 2025

AbbVie dives back into the neuro pool with a $1.2B psychedelics play

Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.

By Michael Gibney • Aug. 26, 2025